Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Rapport Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 3 insiders, $7.55M in total
- Insiders trading
- 3
- Net value
- −$7.55M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Rapport Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer | 456,767 | Sep 24, 2026 | 13 |
| Yeleswaram Krishnaswamy | Chief Development Officer | 195,862 | Aug 26, 2026 | 8 |
| Gault Cheryl | Chief Operating Officer | 149,914 | Jul 1, 2026 | 5 |
| Maraganore John | Director | – | Jun 10, 2026 | 1 |
| Paul Steven M | Director | 41,666Indirect | Jun 10, 2026 | 1 |
| Healy James | Director | 40,851Indirect | Jun 10, 2026 | 1 |
| Perez Robert J | Director | – | Jun 10, 2026 | 1 |
| Silva Paul M | Director | – | Jun 10, 2026 | 1 |
| Huber Reid M | Director | 20,400 | Jun 10, 2026 | 1 |
| Sanchez Ramiro | Director | – | Jun 10, 2026 | 1 |
| Young Wendy B. | Director | 9,500 | Jun 10, 2026 | 1 |
| Third Rock Ventures V, L.P. | 10% Owner | 6,280,525 | May 28, 2026 | 4 |
| Third Rock Ventures VI, L.P. | 10% Owner | 6,280,525 | May 28, 2026 | 4 |
| Third Rock Ventures GP V, LP | 10% Owner | 6,280,525 | May 28, 2026 | 4 |
| Third Rock Ventures GP VI, L.P. | 10% Owner | 6,280,525 | May 28, 2026 | 4 |
| TRV GP VI, LLC | 10% Owner | 6,280,525 | May 28, 2026 | 4 |
| TRV GP V, LLC | 10% Owner | 6,280,525 | May 28, 2026 | 4 |
| Bredt David | Chief Scientific Officer | 393,075 | Feb 19, 2026 | 7 |
| Ignelzi Troy A. | Chief Financial Officer | 10,000 | Feb 4, 2026 | 1 |
| Sevigny Jeffrey | Chief Medical Officer | – | Feb 4, 2026 | 1 |
| Crandell Keith | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| Nelsen Robert | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| Gillis Steven | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| Burow Kristina | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| ARCH Venture Fund XII, L.P. | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| ARCH Venture Partners XII, LLC | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| ARCH Venture Partners XII, L.P. | 10% Owner | 3,728,738Indirect | Jun 10, 2024 | 0 |
| Galer Bradley S. | Chief Medical Officer | – | Jun 10, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)4:09 PM ET | Aug 19 | 1 day | Yeleswaram KrishnaswamyChief Development Officer | SSale | −404 | $49.90 | −$20.2K | −0.2%246.0K after | 10b5-1 |
| Aug 26, 2026 (view filing)4:00 PM ET | Aug 24-25 | 2 days | Yeleswaram KrishnaswamyChief Development Officer | SSale | −50.2K | $50.47 | −$2.53M | −20.4%195.9K after | 3 lots10b5-1 |
| Aug 26, 2026 (view filing)4:05 PM ET | Aug 25 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −18.9K | $49.57 | −$938.0K | −3.9%467.2K after | 10b5-1 |
| Sep 9, 2026 (view filing)4:05 PM ET | Sep 8 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −8.21K | $45.61 | −$374.5K | −1.8%459.0K after | 2 lots10b5-1 |
| Sep 24, 2026 (view filing)4:05 PM ET | Sep 23 | 1 day | Ceesay AbrahamChief Executive Officer | SSale | −2.21K | $39.17 | −$86.6K | −0.5%456.8K after | 3 lots10b5-1 |